The Effects of RPL554 on Top of Standard COPD Reliever Medications

Exclusion Criteria

• •History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
• •COPD exacerbation requiring oral steroids in the previous 3 months
• •History of one or more hospitalisations for COPD in the previous 12 months
• •Respiratory tract infection (both upper and lower) treated with antibiotics in previous 12 weeks
• •Evidence of cor pulmonale or clinically significant pulmonary hypertension.
• •Other respiratory disorders
• •Previous lung resection or lung reduction surgery.
• •Oral therapies for COPD in the previous 3 months and throughout the study.
• •Drug or alcohol abuse in the past 3 years
• •Received an experimental drug within 3 months or five half lives, whichever is longer.
• •Prior exposure to RPL554
• •Patients with a history of chronic uncontrolled disease that the Investigator believes are clinically significant.
• •Documented cardiovascular disease in last 3 months
• •Major surgery, (requiring general anaesthesia) in the previous 6 weeks, or will not have fully recovered from surgery, or planned surgery through the end of the study.
• •History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell)
• •Clinically significant abnormal values for safety laboratory tests
• •A disclosed history, or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications.
• •Requires oxygen therapy, even on an occasional basis.
• •Inability to adequately perform whole body plethysmography.
• •Any other reason that the Investigator considers makes the subject unsuitable to participate.
• •Patients with known hypersensitivity to atropine or its derivatives, or to ipratropium bromide, salbutamol or RPL554 or their excipients/components.